UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000043970 |
|---|---|
| Receipt number | R000050216 |
| Scientific Title | Affect of pharmacist intervention on glycemic control : A Meta-Analysis and Systematic Review |
| Date of disclosure of the study information | 2021/04/20 |
| Last modified on | 2022/12/27 13:03:48 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Affect of pharmacist intervention on glycemic control : A Meta-Analysis and Systematic Review
Acronym
Affect of pharmacist intervention on glycemic control : A Meta-Analysis and Systematic Review
Scientific Title
Affect of pharmacist intervention on glycemic control : A Meta-Analysis and Systematic Review
Scientific Title:Acronym
Affect of pharmacist intervention on glycemic control : A Meta-Analysis and Systematic Review
Region
| Japan |
Condition
Condition
Diabetes mellitus
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Make it clear whether or not reduction in HbA1c of pharmacist interventions.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Reduction in HbA1c
Key secondary outcomes
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
(1)Diabetic patient
(2)Pharmacist interventions
(3)Reduction in HbA1c
(4)Study in japan
Key exclusion criteria
(1)Intervention of Other health occupations
(2)Change of prescription
Target sample size
Research contact person
Name of lead principal investigator
| 1st name | Yumeka |
| Middle name | |
| Last name | WASHIO |
Organization
Chiba Pharmaceutical Association
Division name
Drug Information Center
Zip code
260-0025
Address
9-2 Tonyacho, Chuo-ku, Chiba-shi, Chiba, Japan
TEL
043-247-4401
drug-info@c-yaku.or.jp
Public contact
Name of contact person
| 1st name | Yumeka |
| Middle name | |
| Last name | WASHIO |
Organization
Chiba Pharmaceutical Association
Division name
Drug Information Center
Zip code
260-0025
Address
9-2 Tonyacho, Chuo-ku, Chiba-shi, Chiba, Japan
TEL
043-247-4401
Homepage URL
drug-info@c-yaku.or.jp
Sponsor or person
Institute
Chiba Pharmaceutical Association
Institute
Department
Personal name
Funding Source
Organization
Chiba Pharmaceutical Association
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Not applicable
Address
Not applicable
Tel
Not applicable
Not applicable
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2021 | Year | 04 | Month | 20 | Day |
Related information
URL releasing protocol
N/A
Publication of results
Unpublished
Result
URL related to results and publications
N/A
Number of participants that the trial has enrolled
808
Results
After performing the systematic review for 13 out of 65 articles, it showed that pharmacist intervention continued to result in appropriate HbA1c levels after the end of management.
The three meta-analysis articles in the systematic review that compared before and after intervention showed heterogeneity >25%, so the REM results were adopted. The mean difference was -0.93 (95% confidence interval: -1.68; -0.18).
Results date posted
| 2022 | Year | 12 | Month | 27 | Day |
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
N/A
Participant flow
N/A
Adverse events
N/A
Outcome measures
N/A
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2021 | Year | 04 | Month | 20 | Day |
Date of IRB
| 2021 | Year | 04 | Month | 20 | Day |
Anticipated trial start date
| 2021 | Year | 04 | Month | 20 | Day |
Last follow-up date
| 2021 | Year | 04 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
We will search databases for articles published on the affects of pharmacist interventions on glycemic control, and conduct a meta-analysis and systematic review.
The study does not get approval from Ethical review board because of meta-analysis.
Management information
Registered date
| 2021 | Year | 04 | Month | 19 | Day |
Last modified on
| 2022 | Year | 12 | Month | 27 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050216
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
